Gustave Roussy is the leading cancer center in Europe, representing a comprehensive hub of expertise in oncology. Staffed with 3,100 professionals engaged in patient care, research and teaching, this prestigious academic medical center has partnered with France-based contract research organization (CRO), XenTech to develop a new panel of patient-derived xenograft PDX) models from patients with acquired resistance to last-generation targeted drugs in oncology. These PDX models will be used in Gustave Roussy’s oncology R&D programs as well as being added to Xentech’s existing PDX platform for translational oncology research projects for academic and industry customers.
The Gustave Roussy press release notes that patients with tumors that protect specific driver molecular alterations benefit from targeted therapies, but responses are generally short-lived due to the emergence of adaptive/secondary resistance. Gustave Roussy’s MATCH-R trial will have enrolled 600 patients treated with targeted therapies. Biopsies will be used to generate PDX models, obtained from 300 patients who have developed resistance following initial response. Thereafter, the academic-sponsor shall regularly update the MATCH-R PDX platform with new models, offering a novel resource in unravelling the mechanisms involved in acquired resistance to targeted therapies—as well as the testing of novel therapeutic strategies to circumvent or delay the emergence of resistance. Benjamin Besse, head of the department of medical oncology at Gustave Roussy and principal investigator for the MATCH-R clinical trial mentions” this strategic collaboration with XenTech, a renowned expert in PDX development and in vivo pharmacological studies, is a major asset for Gustave Roussy’s precision medicine program. There is no doubt that these clinically relevant models will speed-up the development of novel therapeutic agents leading to extended clinical benefit for metastatic cancer patients.”